• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Meltz Mark A

    6/11/25 5:40:49 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LYEL alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Meltz Mark A

    (Last) (First) (Middle)
    C/O LYELL IMMUNOPHARMA, INC.
    201 HASKINS WAY, SUITE 101

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/09/2025
    3. Issuer Name and Ticker or Trading Symbol
    Lyell Immunopharma, Inc. [ LYEL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Charles Newton, as Attorney-in-Fact 06/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LYEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LYEL

    DatePrice TargetRatingAnalyst
    10/30/2024$6.00 → $1.00Buy → Underperform
    BofA Securities
    6/27/2024$6.00 → $1.00Buy → Neutral
    H.C. Wainwright
    8/28/2023$15.00 → $5.00Overweight → Neutral
    JP Morgan
    11/14/2022$15.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2022$13.00 → $7.00Buy → Neutral
    Goldman
    10/17/2022$12.00Buy
    H.C. Wainwright
    1/6/2022$25.00 → $20.00Overweight
    Morgan Stanley
    7/12/2021$25.00Buy
    BofA Securities
    More analyst ratings

    $LYEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brawley Otis W bought $19,958 worth of shares (35,640 units at $0.56) (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      4/2/25 3:46:01 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramachandra Sumant bought $115,220 worth of shares (200,000 units at $0.58) (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      3/25/25 6:46:17 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Klausner Richard bought $94,942 worth of shares (158,000 units at $0.60) (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      3/18/25 8:07:51 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    SEC Filings

    See more
    • SEC Form 8-K filed by Lyell Immunopharma Inc.

      8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

      6/9/25 4:23:34 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Lyell Immunopharma Inc.

      8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

      5/28/25 4:00:42 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Lyell Immunopharma Inc.

      8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

      5/21/25 4:05:12 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Financials

    Live finance-specific insights

    See more
    • Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

      Strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845 and earlier-stage TIL programsCash runway following the close of the transaction is expected to fund operations into 2027, through impor

      10/24/24 4:00:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

      Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple

      6/26/24 7:00:00 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

      Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate

      6/9/25 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Ly

      6/4/25 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

      Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in the third- or later-line setting.LYL314 clinical supply now manufactured at Lyell's LyFE Manufacturing Center™, following successful technology transfer and clearance by the FDA of an Investigational

      5/13/25 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

      Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate

      6/9/25 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

      Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues

      8/8/23 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

      SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in compl

      7/5/23 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lyell Immunopharma downgraded by BofA Securities with a new price target

      BofA Securities downgraded Lyell Immunopharma from Buy to Underperform and set a new price target of $1.00 from $6.00 previously

      10/30/24 6:29:00 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $1.00 from $6.00 previously

      6/27/24 7:49:16 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma downgraded by JP Morgan with a new price target

      JP Morgan downgraded Lyell Immunopharma from Overweight to Neutral and set a new price target of $5.00 from $15.00 previously

      8/28/23 7:19:05 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

      SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)

      11/12/24 4:04:21 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

      SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)

      11/4/24 1:30:41 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Lyell Immunopharma Inc.

      SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)

      10/31/24 6:00:17 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bachleda Mark

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      6/11/25 5:48:27 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Meltz Mark A

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      6/11/25 5:47:11 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Shook David was granted 21,900 shares (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      6/11/25 5:45:48 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care